If you take a GLP-1 drug, will retained stomach contents cause you to aspirate during general anesthesia?
Evidence quality 4.0/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 4/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 4/5
- D6 Prose
- 4/5
- D7 Perception honesty
- 3/5
- D8 Caveat completeness
- 4/5
● your factors — click this risk ▾ to reveal
- Your factors
≈ As likely as
Perceived
Press coverage of the 2023 ASA advisory and the November 2024 FDA label warning framed GLP-1 drugs as a serious anesthesia hazard, with headlines urging patients to stop Ozempic or risk aspirating during surgery. The intuitive read is that a GLP-1 user faces a high, near-certain chance of choking on retained stomach contents on the operating table. No survey has measured this specific perception, so the rough estimate is inferred from the alarm in coverage and patient forums, not from polling.
Rough estimate: Patients and media framing imply a perceived per-procedure aspiration risk on the order of several percent to tens of percent ('don't go under on Ozempic').
Source: editorial intuition, not polled
Actual
about 1 in 610 procedures
Adults taking a GLP-1 receptor agonist who undergo an elective procedure requiring general anesthesia or deep sedation
Show derivation
Subgroup: an adult on a GLP-1 receptor agonist undergoing one elective procedure requiring general anesthesia or deep sedation. Basis: PER PROCEDURE, not aggregated over a lifetime of procedures. Point estimate 0.00163 is the pooled aspiration rate in GLP-1 users from the largest endoscopy meta-analysis (143/87,691 = 0.00163). The uncertainty band spans the range of real-world cohorts: the lower bound (~0.0008) approaches the general-population GA baseline (~1 in 8,325 = 0.00012 to ~1 in 2,500 = 0.0004) and the lower cohort estimates; the upper bound (~0.008) reflects the surgical cohort figure of 0.8% (IJS 2025). Crucially this is the ABSOLUTE per-procedure aspiration probability, NOT a GLP-1-attributable excess: the matched control rates (0.12%-0.7%) overlap the GLP-1 rates, and pooled odds ratios (1.07-1.23) are not statistically significant. So the headline number is 'how often a GLP-1 user aspirates,' which is low, while 'how much the drug raises that risk' is null-to-unproven.
Caveats: The headline number is the absolute per-procedure aspiration rate for a GLP-1 us…
The headline number is the absolute per-procedure aspiration rate for a GLP-1 user (about 1 in 610 in the endoscopy meta-analysis, up to about 1 in 125 in the broader surgical cohort), NOT the amount the drug adds to that risk. The two large real-world cohorts and the endoscopy meta-analysis found matched control rates that overlap the GLP-1 rates, with odds ratios (1.07, 1.23) that are not statistically significant, and one nationwide propensity-matched study found GLP-1 users had a lower aspiration rate than non-users. So the drug's attributable excess is null-to-unproven even though the surrogate (retained gastric contents) is markedly elevated (56% vs 19% on ultrasound; risk ratios 2.92 to 15.14). Aspiration events are rare, so per-procedure estimates rest on small numerators and wide confidence intervals; the surgical and endoscopy figures differ by procedure type, urgency, and airway management. The number is scoped per procedure, not per lifetime; a person undergoing many procedures accumulates risk roughly linearly. The 8D self-score clears threshold (avg 4.0), with the main soft spots being perception (intuition-only, no survey) and the per-procedure-vs-lifetime scope translation.
Related risks
Other risks on similar themes — for exploring related fears.
NAION (Ozempic)
What are the odds of sudden permanent vision loss (NAION) from taking semaglutide (Ozempic/Wegovy)?
Unsafe imported products
What are the odds of being harmed by an unsafe imported consumer product?
Childhood cancer diagnosis
What are the odds of a child being diagnosed with cancer before age 20?
Counterfeit medicine
What are the odds of being harmed or killed by a counterfeit or substandard medicine?
Decisions this risk informs
Choices that turn on this risk — how people weigh the trade-off.
Pick challenger
The fear here is mechanically plausible and clinically documented at the level of the stomach. GLP-1 receptor agonists slow gastric emptying, and point-of-care ultrasound confirms the consequence: in a 2024 JAMA Surgery cohort, 56 percent of GLP-1 users had retained gastric contents before anesthesia against 19 percent of non-users, an adjusted increase of 30.5 percent. Across smaller ultrasound studies the risk ratios for retained content run from about 2.92 to 15.14. The 2023 ASA advisory, the October 2024 multisociety guidance, and a November 2024 FDA label change all responded to this, and the coverage that followed framed the drugs as a reason to fear going under.
What that machinery does not show up as is a matching surge in actual aspiration. Pulmonary aspiration under anesthesia is rare to begin with, on the order of 1 in 8,325 anesthetics in a 166,491-record baseline cohort. In GLP-1 users the measured per-procedure rate sits low: a 2025 meta-analysis of elective endoscopy found aspiration in 143 of 87,691 GLP-1 users, about 1 in 610, against 149 of 122,525 controls, with an odds ratio of 1.23 that did not reach significance. A separate surgical cohort of 392,065 patients put the figure at 0.8 percent in users versus 0.7 percent in non-users, adjusted odds ratio 1.07, no association. A nationwide propensity-matched study reported a lower aspiration rate in users than non-users. The retained-content surrogate is elevated; the outcome it is supposed to predict is not, at least not measurably.
The number this entry publishes is the absolute chance that a GLP-1 user aspirates during one procedure, which is low. It is deliberately not the same as the chance the drug adds, which the cohort data leaves null or unproven. The guidance reflects that split: the 2024 multisociety statement leans toward continuing the drug for most patients and reserving extra precautions, a clear-liquid diet, an extended fast, or an ultrasound look at the stomach, for those in the dose-escalation phase, on weekly high doses, or with active nausea and bloating. Those precautions target the inflated surrogate. The aspiration events that would justify the original alarm have so far stayed close to the background rate that anesthesia carries with or without these drugs.
Related tidbits
Pulmonary aspiration during anesthesia in GLP-1 users runs at about 1 in 610 procedures. Headlines frame the delayed stomach-emptying risk as a reason to fear surgery; the surrogate-endpoint rate is lower than the alarm implies.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] JAMA Surgery — Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia
Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia- Statistic
GLP-1 RA use associated with a 30.5% (95% CI, 9.9%-51.2%) higher prevalence of increased residual gastric content; 56% (35/62) vs 19% (12/62).- Excerpt
“GLP-1 RA use was associated with a 30.5% (95% CI, 9.9%-51.2%) higher prevalence of increased RGC”
- Source data from
- 2024-03-06
- Accessed
- 2026-06-13
- Calculation
- This is the SURROGATE (retained gastric content), not aspiration. Raw prevalence 56% vs 19%; adjusted difference +30.5%. Increased RGC defined as solids, thick liquids, or >1.5 mL/kg clear liquids on ultrasound. Authors note they 'did not directly assess aspiration events, which are rare.' Used to establish the elevated-surrogate half of the perceived-vs-actual gap, not the headline number.
- Independence
- University of Texas Houston cohort; independent of the endoscopy and surgery aspiration cohorts below.
-
[2] The Open Respiratory Medicine Journal — GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis
GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis- Statistic
Pulmonary aspiration in 143/87,691 (0.16%) GLP-1 users vs 149/122,525 (0.12%) controls; OR 1.23 (95% CI 0.58-2.60; P=0.59), not significant.- Excerpt
“143 of 87,691 patients (0.16%) in the GLP-1 agonist group and 149 of 122,525 patients (0.12%) in the placebo group had pulmonary aspiration.”
- Source data from
- 2025-06-11
- Accessed
- 2026-06-13
- Calculation
- Source of the native counts and the normalized point estimate. 143/87,691 = 0.00163. Control rate 149/122,525 = 0.00122 overlaps, OR 1.23 not significant -> the absolute rate is low and the excess is unproven. Point estimate = 0.00163; log10 = -2.788.
- Independence
- Pooled endoscopy meta-analysis; distinct dataset from the surgical TriNetX/IJS cohorts.
-
[3] International Journal of Surgery — Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery
Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery- Statistic
Aspiration 0.8% in GLP-1 users vs 0.7% non-users (P=0.61); adjusted OR 1.07 (95% CI 0.85-1.34), no association. N=392,065 (15,745 users).- Excerpt
“After adjusting for other risk factors for aspiration, there was no association between GLP-1 agonist use and aspiration (OR = 1.07; 95% CI, 0.85–1.34).”
- Source data from
- 2025-05-12
- Accessed
- 2026-06-13
- Calculation
- Supplies the upper end of the uncertainty band (0.8% = 0.008). Surgical population (2015-2022), broader than endoscopy, so higher absolute aspiration rate. Confirms the null excess: OR 1.07 not significant.
- Independence
- Separate surgical cohort; conclusion converges with the endoscopy meta despite independent data.
-
[4] Journal of the Endocrine Society — Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk
Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk- Statistic
Across cohorts, aspiration ~2.6-8.3 per 1000 in GLP-1 users vs similar in non-users; retained-content risk ratios 2.92-15.14; ASA Oct 29 2024 guidance.- Excerpt
“retrospective cohort studies using large real-world evidence databases have not consistently identified a GLP-1RA-associated risk of aspiration/pneumonia for elective surgical and endoscopic procedures”
- Source data from
- 2025-07-10
- Accessed
- 2026-06-13
- Calculation
- Review consolidating the field: per-procedure aspiration 2.61-8.32 per 1000 in users (0.0026-0.0083), bracketing the chosen band; retained-content RRs 2.92-15.14 (the elevated surrogate). Source for the multisociety guidance summary and the 'continue most patients, shared decision making' framing.
- Independence
- Narrative review summarizing the primary cohorts above; cited for synthesis and guidance context, not as an independent dataset.
-
[5] Annals of Palliative Medicine — Perioperative pulmonary aspiration and regurgitation without aspiration in adults: a retrospective observational study of 166,491 anesthesia records
Perioperative pulmonary aspiration and regurgitation without aspiration in adults: a retrospective observational study of 166,491 anesthesia records- Statistic
Perioperative aspiration in 20/166,491 anesthetics (1:8,325); morbidity 1:16,649; mortality 1:55,497.- Excerpt
“Among the 166,491 anesthesia records, 20 patients had PA (1:8,325)”
- Source data from
- 2021-04-30
- Accessed
- 2026-06-13
- Calculation
- General-population baseline aspiration rate under anesthesia (1:8,325 = 0.00012), pre-dating the GLP-1 era. Establishes the lower edge / reference point: GLP-1-user rates (0.0016-0.008) sit near or modestly above this baseline, consistent with the null-excess finding. Used for the lower uncertainty bound and severity context.
- Independence
- Baseline cohort with no GLP-1 exposure measured; independent of all GLP-1 sources.
-
[6] Pharmacy Times — FDA Adds Delayed Gastric Emptying as Adverse Event on Semaglutide Label
FDA Adds Delayed Gastric Emptying as Adverse Event on Semaglutide Label- Statistic
FDA added a label warning of rare postmarketing reports of pulmonary aspiration in GLP-1 users undergoing anesthesia despite reported fasting (Nov 2024).- Excerpt
“postmarking reports showing rare instances of pulmonary aspiration for patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists and undergoing elective surgeries or procedures that require general anesthesia or deep sedation”
- Source data from
- 2024-11-14
- Accessed
- 2026-06-13
- Calculation
- Documents the FDA regulatory action (label 'rare instances' language) that drives the public-perception half of the entry. Non-authoritative news source; used only for the FDA/labeling timeline, not for any rate.